Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Cancer
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application PCT/EP2013/001503, filed May 21, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,433,675 | Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Cancer In force · High confidence | Astellas Pharma Inc. | In force | High confidence | ||
| US 10,022,444 | Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Cancer In force · High confidence | Astellas Pharma Inc. | In force | High confidence | ||
| US 10,813,996 | Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Cancer In force · Low confidence | Astellas Pharma Inc. | In force | Low confidence | ||
| US 12,059,464 | Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Cancer In force · Medium confidence | Astellas Pharma Inc. | In force | Medium confidence | ||
| Application 18/757,437 | Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Cancer Pending Not granted | Astellas Pharma Inc. | Pending | Not granted |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Astellas Pharma Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.